PT  - JOURNAL ARTICLE
AU  - Timo Weiss
AU  - Tarek Sabha
AU  - Jens Kollmeier
AU  - Torsten Blum
AU  - Harald Mauch
AU  - Holger Rüssmann
AU  - Nicolas Schönfeld
AU  - Torsten T. Bauer
TI  - In vitro susceptibility of M. avium against protionamide
DP  - 2011 Sep 01
TA  - European Respiratory Journal
PG  - p4415
VI  - 38
IP  - Suppl 55
4099  - http://erj.ersjournals.com/content/38/Suppl_55/p4415.short
4100  - http://erj.ersjournals.com/content/38/Suppl_55/p4415.full
SO  - Eur Respir J2011 Sep 01; 38
AB  - Introduction: M. avium is a potentially pathogenic mycobacterial species to humans, which is classified as difficult to cure. By the American Thoracic Society resistance testing in vitro in the case of newly diagnosed mycobacteriosis is recommended only for clarithromycin, but with treatment failure is shown the option for further testing. No data were so far reported for the the susceptibility of M. avium to protionamide in vitro in the literature.Methods: All M. avium strains that could be isolated from clinical materials in our laboratory from Jan 1st 2008 to May 31st 2010, were subjected to susceptibility testing on solid media according to DIN 58943rd.Results: Out of 67 strains only one turned out to be resistant at an inhibitory concentration of 5 micrograms/ml protionamide. While only one further strain showed resistance to clarithromycin (32 mcg/ml), 18 strains showed resistance to moxifloxacin (4 mcg/ml).Conclusions: Despite the absence of clinical treatment studies protionamide should be considered as a treatment option for mycobacteriosis by M. avium in the case of treatment failure or intolerance of a drug of first-line therapy.